Bone Net Receivables from 2010 to 2025

BBLGW Stock  USD 20.20  0.00  0.00%   
Bone Biologics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 345.3 K in 2025. During the period from 2010 to 2025, Bone Biologics Net Receivables regression line of quarterly data had mean square error of 26.6 B and geometric mean of  253,270. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
378.2 K
Current Value
345.3 K
Quarterly Volatility
217.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 11.4 M, Total Operating Expenses of 4.7 M or Gross Profit of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 1.8 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Latest Bone Biologics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Bone Biologics Corp over the last few years. It is Bone Biologics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Bone Net Receivables Regression Statistics

Arithmetic Mean340,668
Geometric Mean253,270
Coefficient Of Variation63.74
Mean Deviation184,701
Median345,318
Standard Deviation217,153
Sample Variance47.2B
Range504.9K
R-Value0.69
Mean Square Error26.6B
R-Squared0.47
Significance0
Slope31,368
Total Sum of Squares707.3B

Bone Net Receivables History

2025345.3 K
2024378.2 K
2023328.8 K
2017579.9 K
2015271.9 K

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables378.2 K345.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.